About this event
Every day a drug discovery team waits for protein is a day the pipeline stalls. AbbVie, a Top 5 Pharma leader, isn't just "trying" cell-free expression—they are using it to shatter traditional timelines.
In this exclusive session, Dr. Judith Ronau reveals the exact workflow her team is using to validate a complex CRISPR hit (Ligase X and 48 mutants) in just 8 weeks.
This isn't a theory. This is a blueprint. Dr. Ronau will show data proving that "bespoke" cell-free reagents aren't just faster—they are decision-grade. You will see how her team bypassed the "make-vs-buy" bottleneck, screened custom additives to rescue "impossible" proteins, and delivered biochemical proof-of-concept while competitors would still be cloning plasmids.
Hosted by
Nuclera empowers researchers to accelerate discovery with rapid, in-house access to high-quality functional proteins.
